Martin Friedlander

1 month ago | ophthalmologytimes.com | Martin Friedlander |Anat Loewenstein |Mohammad Rafieetary |Sheryl Stevenson

The approval of revakinagene taroretcel-lwey (Encelto; Neurotech Pharmaceuticals) as the first and only FDA-approved treatment for macular telangiectasia type 2 (MacTel) marks a significant milestone for patients with the progressive retinal disease.1 The implantable device uses encapsulated cell therapy (ECT) technology to continuously deliver therapeutic doses of ciliary neurotrophic factor (CNTF) to the retina, helping to slow disease progression.The approval was based on the results from...

2 months ago | ophthalmologytimes.com | Martin Friedlander |Sheryl Stevenson

Martin Friedlander, MD, PhD, discusses phase 3 macular telangiectasia findings, highlighting the potential for a decade-long alternative to intravitreal injections.